TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33490863

Group type: EXPERIMENTAL
Intervention: Clinical variables and genome-wide variants
Number of subjects: 2799

Group type: EXPERIMENTAL
Intervention: Genomic analyses
Number of subjects: 2799
Study: 33491053

Group type: EXPERIMENTAL
Intervention: Pulmonary resection
Number of subjects: 44
Study: 33491277

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) intravenously every 21 days
Number of subjects: 12
Study: 33491317

Group type: EXPERIMENTAL
Intervention: PwO perceptions
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: HCP perceptions
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Motivation to lose weight
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: HCP perceptions of PwO motivation
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Barriers to discussing weight
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Discussion of weight with HCPs
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Main barrier to weight loss
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Successful weight loss
Number of subjects: 2000
Study: 33491668

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) at a dosage of 1 × 10^6 to 3 × 10^6 cells/kg, administered as 3 injections every 2 weeks for 8-24 months.
Number of subjects: 6
Study: 33492231

Group type: EXPERIMENTAL
Intervention: mHealth intervention (6-month duration)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 450
Study: 33492239

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneously administered methotrexate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Daily oral azathioprine or 6-mercaptopurine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered adalimumab (ADA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Children's school attendance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Parents' productivity (WPAI-CD-CG questionnaire)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measurements using EuroQol 5-Dimension questionnaires
Number of subjects: 12
Study: 33492438

Group type: EXPERIMENTAL
Intervention: AR-42, 60 mg three times weekly for 3 weeks of a 28-day cycle
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AR-42
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AR-42 in patients with NF2 or meningioma
Number of subjects: 17
Study: 33492554

Group type: EXPERIMENTAL
Intervention: Biosynthetic long-term absorbable mesh (Phasix®)
Number of subjects: 215
Study: 33492745

Group type: EXPERIMENTAL
Intervention: Antegrade placement of fistula needle
Number of subjects: 164
Study: 33492893

Group type: EXPERIMENTAL
Intervention: Remote ocular assessment consisting of visual acuity, intraocular pressure, visual field testing, and imaging of the retina and optic nerve with spectral-domain optical coherence tomography.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial incentives along with a validated patient education program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine program.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard in-person care.
Number of subjects: 0
Study: 33492986

Group type: EXPERIMENTAL
Intervention: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion until disease progression or unacceptable toxicity
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion
Number of subjects: 190
Study: 33493046

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4654

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4654

Group type: EXPERIMENTAL
Intervention: Overall treatment effect (CAS-to-CEA)
Number of subjects: 4654
Study: 33493297

Group type: EXPERIMENTAL
Intervention: Cumulative exposure to elvitegravir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative exposure to raltegravir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative exposure to stavudine
Number of subjects: 0
Study: 33493312

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab (80 mg/m2 at weeks 0, 4, then every 8 weeks through week 52 plus MTX weekly through week 28)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab
Number of subjects: 127
Study: 33493377

Group type: EXPERIMENTAL
Intervention: Gastroparesis patients
Number of subjects: 715
Study: 33493392

Group type: EXPERIMENTAL
Intervention: Ivosidenib (100 mg twice daily and 300-1200 mg once daily)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 253
Study: 33493590

Group type: EXPERIMENTAL
Intervention: Vascular surgery procedures in patients with COVID-19 infection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Age >65 years
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ASA classification IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preoperative lymphocyte count <0.6 (×10^9/L)
Number of subjects: 75
Study: 33493688

Group type: EXPERIMENTAL
Intervention: Post-procedure tramadol
Number of subjects: 1335

Group type: EXPERIMENTAL
Intervention: Post-procedure epidural opioids
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Short-acting opioids
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Long-acting opioids
Number of subjects: 1335
Study: 33493697

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral agents (DAAs) leading to sustained virologic response (SVR)
Number of subjects: 854
Study: 33493778

Group type: EXPERIMENTAL
Intervention: Greater positive symptoms
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Stronger working memory
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Impaired clinical insight
Number of subjects: 404
Study: 33493822

Group type: EXPERIMENTAL
Intervention: Apraxia of Speech Rating Scale (ASRS) administered by five speech-language pathologists (SLPs)
Number of subjects: 36
Study: 33494702

Group type: EXPERIMENTAL
Intervention: Early upper limb passive ergometry for 30 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reverse Fick method
Number of subjects: 12

Group type: COMPARATOR
Intervention: Indirect calorimetry
Number of subjects: 12
Study: 33494707

Group type: EXPERIMENTAL
Intervention: Patients with cardiovascular events during hospitalization for CAP
Number of subjects: 1266

Group type: COMPARATOR
Intervention: Patients without cardiovascular events during hospitalization for CAP
Number of subjects: 1266
Study: 33494793

Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 62
Study: 33494821

Group type: EXPERIMENTAL
Intervention: Ad-Shoulder intervention consisting of 1-5 individual sessions over 3 months based on 5 self-management skills.
Number of subjects: 11
Study: 33494961

Group type: EXPERIMENTAL
Intervention: Modified HEART score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard risk stratification methods
Number of subjects: 0
Study: 33494963

Group type: EXPERIMENTAL
Intervention: Low dose recombinant full-length circumsporozoite protein-based vaccine with GLA-LSQ adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33495083

Group type: EXPERIMENTAL
Intervention: Recording an obesity diagnosis in medical notes
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Comfort discussing weight with patients
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Feeling motivated to help patients lose weight
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Lack of advanced formal training in obesity management
Number of subjects: 2331
Study: 33495144

Group type: EXPERIMENTAL
Intervention: Major bleeding (MB) following LAAO
Number of subjects: 0
Study: 33495264

Group type: EXPERIMENTAL
Intervention: Prognostic clinical prediction model combining simple clinical features and measurements of host biomarkers
Number of subjects: 4900

Group type: EXPERIMENTAL
Intervention: Clinical outcome ascertained on day 2 and day 28
Number of subjects: 4900
Study: 33495293

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for maternal GDM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no lifestyle intervention)
Number of subjects: 0
Study: 33495292

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 157

Group type: COMPARATOR
Intervention: HbA1c monitoring
Number of subjects: 157
Study: 33495309

Group type: EXPERIMENTAL
Intervention: Prexasertib + samotolisib
Number of subjects: 0
Study: 33495312

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus tranylcypromine (TCP) at three dose levels: 10 mg twice daily, 20 mg twice daily, and 30 mg twice daily.
Number of subjects: 17
Study: 33495385

Group type: EXPERIMENTAL
Intervention: Remote-only follow-up with Remote View service
Number of subjects: 176
Study: 33495476

Group type: EXPERIMENTAL
Intervention: Prior treatments
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Microsatellite instability
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: CRC-specific 1kb-10Mb deletions and LINC00672 mutations
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: FBXW7 mutations
Number of subjects: 429
Study: 33495497

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Conventional therapy (CT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 133
Study: 33495742

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulses and tacrolimus plus standard of care (SoC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 84
Study: 33495752

Group type: EXPERIMENTAL
Intervention: Ivermectin 400 mcg/kg, single dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33496186

Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy (ET)
Number of subjects: 7674

Group type: COMPARATOR
Intervention: Bridging Thrombolysis (BT)
Number of subjects: 7674
Study: 33496191

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging at baseline and at 6 months
Number of subjects: 187
Study: 33496357

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 26
Study: 33496659

Group type: EXPERIMENTAL
Intervention: Anaphylaxis management guidelines
Number of subjects: 0
Study: 33496677

Group type: EXPERIMENTAL
Intervention: Fitbit Zip activity tracker worn daily for 8 weeks (2 weeks prior to surgery and 6 weeks post-surgery)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fitbit Zip worn as a clip-on device
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 62
Study: 33496745

Group type: EXPERIMENTAL
Intervention: CALGB 10403
Number of subjects: 39

Group type: COMPARATOR
Intervention: COG AALL0232
Number of subjects: 39
Study: 33496747

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily for 14 days per cycle combined with 8 cycles of CHOP21
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lenalidomide and CHOP
Number of subjects: 78
Study: 33496754

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate or cryoprecipitate replacement for hypofibrinogenemia
Number of subjects: 137

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 137
Study: 33496877

Group type: EXPERIMENTAL
Intervention: Dobutamine-sparing strategy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dobutamine-to-all strategy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 33496906

Group type: EXPERIMENTAL
Intervention: Trendelenburg maneuver (15° downward bed angulation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fluid challenge (500 mL gelatin over 15 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline-1 (supine position with 15° upward bed angulation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline-2 (same position as baseline-1)
Number of subjects: 22
Study: 33497021

Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time for male patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time for patients with intradialytic hypotension (IDH)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time by gender
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BMI in relation to post-dialysis recovery time
Number of subjects: 86
Study: 33497061

Group type: EXPERIMENTAL
Intervention: REPS (Residual Neuromuscular Block Prediction Score) high (≥4)
Number of subjects: 101510

Group type: COMPARATOR
Intervention: TOF ratio <0.90
Number of subjects: 101510

Group type: EXPERIMENTAL
Intervention: REPS high (≥4)
Number of subjects: 101510
Study: 33497524

Group type: EXPERIMENTAL
Intervention: Gene correction of the c.175G>A variant in patient-derived iPSCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control iPSCs (coisogenic, corrected variant)
Number of subjects: 0
Study: 33497776

Group type: EXPERIMENTAL
Intervention: Theta-burst TMS to OPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theta-burst TMS to OFA (active control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham (no TBS stimulation)
Number of subjects: 0
Study: 33498192

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC) determined by Agatston and volume score
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Abdominal aorta calcification (KS) determined by plain X-ray of the lumbar spine
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Presence and extension of vascular calcification (VC)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: CAC and KS
Number of subjects: 184
Study: 33498797

Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole (P+L)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Palbociclib + Fulvestrant (P+F)
Number of subjects: 247
Study: 33499647

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program (12 weeks, 3 sessions per week)
Number of subjects: 29
Study: 33500704

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) with or without adefovir (ADV) for 104 weeks
Number of subjects: 24
Study: 33500784

Group type: EXPERIMENTAL
Intervention: Baseline objective clinical scoring (SCAT5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurocognitive data (ImPACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes to SCAT5 and ocular, vestibular, and reaction time function (Dx 100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments (CANTAB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain MRI (7 Tesla)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salivary biomarkers
Number of subjects: 0
Study: 33501400

Group type: EXPERIMENTAL
Intervention: 6 weekly doses of lyophilized fecal microbiota product from healthy donors
Number of subjects: 6
Study: 33501650

Group type: EXPERIMENTAL
Intervention: Urgent-start peritoneal dialysis (PD)
Number of subjects: 991

Group type: COMPARATOR
Intervention: Haemodialysis (HD) initiated using a CVC
Number of subjects: 991
Study: 33501995

Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat with rilpivirine and/or dolutegravir
Number of subjects: 725

Group type: COMPARATOR
Intervention: darunavir/cobicistat alone
Number of subjects: 725
Study: 33501999

Group type: EXPERIMENTAL
Intervention: Pregnancy in women with LGMDR9
Number of subjects: 22
Study: 33502092

Group type: EXPERIMENTAL
Intervention: Heartech® left ventricular partitioning device (LVPD)
Number of subjects: 15
Study: 33502111

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (0.03 mg/kg) administered twice daily starting 3 days prior to transplant
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Dosing simulation strategy based on observed tacrolimus concentration
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Covariate analysis
Number of subjects: 252
Study: 33502330

Group type: EXPERIMENTAL
Intervention: Mobile sensing features (call logs, battery charging, screen checking)
Number of subjects: 26
Study: 33502567

Group type: EXPERIMENTAL
Intervention: Ultra-Low Doses of Therapy with Radiation (ULTRA-COVID)
Number of subjects: 2
Study: 33502675

Group type: EXPERIMENTAL
Intervention: Self-reported overall sitting time
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Self-reported sum of different types of sedentary behavior
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Device-based sedentary time (Actigraph GT3X accelerometers)
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Correlation coefficients and ICC between self-reported and device-based measures
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Bland-Altman plots
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 2524
Study: 33502773

Group type: EXPERIMENTAL
Intervention: Anticoagulants (all types)
Number of subjects: 5929

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose anticoagulants
Number of subjects: 5929
Study: 33502920

Group type: EXPERIMENTAL
Intervention: Postrelapse radiation therapy among previously nonirradiated SJYC07 patients
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Reirradiation for SJMB03 patients
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Group 4 tumors
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patient-matched tumor pairs
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Subgroup and subtype stability
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Rare subgroup divergence
Number of subjects: 127
Study: 33503046

Group type: EXPERIMENTAL
Intervention: CYP2C19 polymorphism genotyping
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Increased PPI doses or use of PPIs not metabolized by CYP2C19 (rabeprazole)
Number of subjects: 239
Study: 33503342

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (52-mg)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Copper IUD (T380A)
Number of subjects: 711
Study: 33503481

Group type: EXPERIMENTAL
Intervention: Multiview latent analysis method, group factor analysis
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Self-report measures of positive and negative valence
Number of subjects: 476
Study: 33503568

Group type: EXPERIMENTAL
Intervention: sEH-derived fatty acid diols in depressed participants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12(13)-EpOME and 10(11)-EpDPE in depressed participants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ratio of 12,13-DiHOME/12(13)-EpOME in depressed participants
Number of subjects: 40
Study: 33504077

Group type: EXPERIMENTAL
Intervention: Respondent-driven sampling (RDS) to invite individuals for HCV testing
Number of subjects: 51

Group type: COMPARATOR
Intervention: Reference group methodology for outreach
Number of subjects: 51
Study: 33504514

Group type: EXPERIMENTAL
Intervention: ECG-based risk assessment tool
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: ECG predictors (heart rate, QTc-interval, rhythm, atrioventricular block, ST-segment depression, bundle branch block, ventricular extrasystole/non-sustained ventricular tachycardia)
Number of subjects: 2007
Study: 33504920

Group type: EXPERIMENTAL
Intervention: Large diameter scleral lenses
Number of subjects: 13
Study: 33505178

Group type: EXPERIMENTAL
Intervention: Remote autorefraction with pupillary diameter and age as target, using a donated spectacle with a 'B' grade similarity.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Best corrected acuity at 20/20.
Number of subjects: 10
Study: 33505222

Group type: EXPERIMENTAL
Intervention: Injured ankles (acute intra-articular fractures)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy contralateral ankles
Number of subjects: 55

Group type: COMPARATOR
Intervention: Serum cytokine levels
Number of subjects: 55
Study: 33505321

Group type: COMPARATOR
Intervention: Omega-3 Polyunsaturated Fatty Acids supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33505715

Group type: EXPERIMENTAL
Intervention: Conjunctival autografting augmented with topical application of MMC (0.2 mg/mL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conjunctival autografting augmented with Ologen implantation
Number of subjects: 63
Study: 33505726

Group type: EXPERIMENTAL
Intervention: 2 l/min supplemental oxygen during bronchoscopy
Number of subjects: 92

Group type: COMPARATOR
Intervention: No oxygen administration during bronchoscopy
Number of subjects: 92
Study: 33505995

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33506139

Group type: EXPERIMENTAL
Intervention: Limited access SAVR via J-shaped upper hemi-sternotomy (UHS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional SAVR through full median sternotomy (FMS)
Number of subjects: 80
Study: 33506177

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab combined with laser (G2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laser treatment (G1)
Number of subjects: 32
Study: 33506571

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg twice daily
Number of subjects: 45
Study: 33506635

Group type: EXPERIMENTAL
Intervention: Molidustat (75 mg once daily, adjusted to maintain Hb target of ≥10.0 to <12.0 g/dL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Molidustat (dose-titrated for 24 weeks)
Number of subjects: 25
Study: 33506766

Group type: EXPERIMENTAL
Intervention: Targeted methylation analysis of circulating cell-free DNA (cfDNA)
Number of subjects: 6689
Study: 33506990

Group type: EXPERIMENTAL
Intervention: Prognostic risk score developed using clinical, laboratory, and imaging data
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Multivariable models using nine independent predictors of mortality
Number of subjects: 600
Study: 33507158

Group type: EXPERIMENTAL
Intervention: Step-by-Step e-intervention (5 sessions, guided by trained nonspecialist 'e-helpers')
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 1136
Study: 33507454

Group type: EXPERIMENTAL
Intervention: Mavorixafor 400 mg daily plus nivolumab 240 mg every 2 weeks
Number of subjects: 9